Dr. Wenqing Zhang

Oncology | Hematology
521 N Lecanto Hwy, Florida Cancer Specialists, 
Lecanto, FL 
Accepting New Patients
Offers Telehealth
521 N Lecanto Hwy, Florida Cancer Specialists, 
Lecanto, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Wenqing Zhang is an Oncologist and a Hematologist in Lecanto, Florida. Dr. Zhang is rated as an Experienced provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Human Monocytic Ehrlichiosis, Lung Cancer, Pleuropulmonary Blastoma, Anemia, and Bone Marrow Aspiration. Dr. Zhang is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Hca Florida Citrus Hospital
Tampa General Hospital Crystal River
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
521 N Lecanto Hwy, Florida Cancer Specialists, Lecanto, FL 34461

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
View 6 Less Clinical Trials

11 Total Publications

Development of mRNA-lipid nanoparticle intrabodies against rickettsial infection.
Development of mRNA-lipid nanoparticle intrabodies against rickettsial infection.
Journal: Journal of biomedical science
Published: April 14, 2025
Similar Doctors
Distinguished in Subacute Combined Degeneration
Dr. Daniel A. Patterson
Hematology Oncology | Hematology | Oncology
Distinguished in Subacute Combined Degeneration
Dr. Daniel A. Patterson
Hematology Oncology | Hematology | Oncology
3256 S Pine Ave, Suite 303, 
Ocala, FL 
 (29.4 miles away)
352-512-0688
Experience:
44+ years
Languages Spoken:
English, Russian, Spanish
See accepted insurances
Accepting New Patients

Daniel Patterson is a Hematologist Oncology specialist and a Hematologist in Ocala, Florida. Dr. Patterson has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Anemia, Lymphoid Hyperplasia, Thrombocytopenia, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Patterson is currently accepting new patients.

Advanced in Subacute Combined Degeneration
Dr. David D. Wright
Oncology | Hematology | Hematology Oncology
Advanced in Subacute Combined Degeneration
Dr. David D. Wright
Oncology | Hematology | Hematology Oncology

Florida Cancer Specialists And Research Institute, LLC

3402 W Dr Martin Luther King Jr Blvd, Florida Cancer Specialists, 
Tampa, FL 
 (61.3 miles away)
813-875-3950
Languages Spoken:
English, French, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Wright is an Oncologist and a Hematologist in Tampa, Florida. Dr. Wright is rated as a Distinguished provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Childhood Iron Deficiency Anemia, and Pleuropulmonary Blastoma. Dr. Wright is currently accepting new patients.

Advanced in Subacute Combined Degeneration
Dr. Aaron C. Denson
Hematology Oncology | Hematology | Oncology
Advanced in Subacute Combined Degeneration
Dr. Aaron C. Denson
Hematology Oncology | Hematology | Oncology

Comprehensive Hematology Oncology LLC

3611 Little Rd, 
Trinity, FL 
 (46.7 miles away)
727-344-6569
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Denson is a Hematologist Oncology specialist and a Hematologist in Trinity, Florida. Dr. Denson is rated as a Distinguished provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Lung Cancer, and Agranulocytosis. Dr. Denson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhang's expertise for a condition
ConditionClose
      View All 18 Advanced Conditions
      View All 111 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile